ImmunXperts offers services to support researchers in the risk assessment and mitigation of drug candidate’s immunogenicity profile.
ImmunXperts offers services to support researchers in the risk assessment and mitigation of drug candidate’s immunogenicity profile.
DLVR Therapeutics is developing an innovative, HDL-like Peptide-Phospholipid Scaffold (HPPS) nanoparticle delivery system, initially for RNAi therapeutics.